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We compared a direct fluorescent-antibody stain (DFA) and an enzyme immunoassay (EIA) with a standard
cell culture technique for the detection of Chlamydia trachomatis infection in women in an urban family practice
setting. We also evaluated a DFA sample in a commercial laboratory to determine the interlaboratory
reliability of this test. There were 268 women in the study; the EIA provided a higher sensitivity (83 versus
50%) and a higher positive predictive value (83 versus 69%) than the DFA test and comparably high specificity
(99 versus 98%). Concordance between the two laboratories on the DFA test was not high when data were
adjusted for chance agreement (kappa coefficient = 0.64). DFA validity was optimal with an elementary body
cutoff of greater than 5, while EIA validity was optimal at the recommended cutoif of 0.1 optical density unit.
None of Il women with negative cultures after treatment had false-positive antigen tests. False-negative results
with both tests were associated with low culture inclusion counts but were not strongly associated with the
presence or absence of symptoms, menses, pregnancy, or recent antibiotic use. False-positive results with EIA
were seen only for three women who had a chief complaint of vaginal discharge. Although the positive
predictive value ofDFA could be increased in high-prevalence subpopulations, EIA was still more valid in two
such groups: teenagers and prenatal patients. These results indicate that EIA might be preferable for low- or
moderate-prevalence populations in primary care settings and that a falloff in DFA sensitivity could be
explained by lower infection burdens in low-prevalence groups.
Chlamydia trachomatis is responsible for approximately
four million infections each year in the United States, far
more than any other sexually transmitted disease (3). The
sequelae of initial infection with C. trachomatis include the
majority of cases of pelvic inflammatory disease, tubal
infertility, epididymitis, and neonatal infection of the eye
and lung (3). These facts, combined with the introduction of
culture-free antigen detection tests in recent years, have
stimulated a great deal of interest in widespread screening
for chlamydial infection in primary care settings. Current
recommendations state that screening of women in popula-
tions of low to moderate risk should be considered (3).
However, the proper method, target populations, and pro-
cedures for screening in primary care settings have yet to be
established (7).
Several studies have determined the validity of the direct
fluorescent-antibody stain (DFA) and the enzyme immu-
noassay (EIA) by comparing the results from each test alone
with culture results (for a review, see reference 15). These
studies have found wide variation in the sensitivity and
specificity of each method. Only four studies to date have
simultaneously compared direct immunofluorescent stain
and EIA with culture (1, 4, 14, 16). Furthermore, nearly all
previous studies of test validity for women have been
conducted in high-risk populations, such as those with a high
prevalence of infection in sexually transmitted disease and
adolescent referral clinics. In this article, we report the
results of a direct comparison of the DFA test and EIA to
culture in an urban primary care setting with a relatively low
prevalence of infection.
Recent analyses of the cost-effectiveness of the antigen
detection methods have concluded that widespread screen-
ing of low-risk populations might be economically feasible
* Corresponding author.
(9, 10, 19). The test validity assumptions used in these
analyses have not always been verified in actual low-risk
populations. Moreover, false-negative or false-positive re-
sults with antigen methods could arise from factors such as
prior antibiotic treatment and cross-reactions between an-
tichlamydial antibodies and bacterial antigens. We therefore
explored associations between the occurrence of false re-
sults and characteristics of the patient or the test condi-
tions-such as pregnancy, menses, smoking, or recent anti-
biotic use-that could interfere with the antigen tests by
altering the cervical milieu. In addition, because the DFA
test relies on visual pattern recognition by a technologist, we
compared the results when two samples from the same
patient were evaluated at two different laboratories. The
efficacy and efficiency of a test are influenced by the criteria
for the designation of a positive result and by disease
prevalence in selected subpopulations. We therefore ana-
lyzed our data to determine optimal cutoff values for each
antigen test and investigated whether the antigen tests per-
formed better among women who were younger, were
pregnant, or had presumptive signs of infection.
MATERIALS AND METHODS
Patient population. Seven family practice physicians and
three nurse practitioners at a neighborhood health center
affiliated with the University of Massachusetts Medical
Center, Worcester, agreed to participate in the study. To be
eligible for the study, each patient was determined to need a
pelvic exam for any reason during the visit. All eligible
patients seen during a session were enrolled or, during some
sessions, a random sample was selected. A total of 286
women enrolled in the study. The population sample in-
cluded 19% under age 20 and 24% over age 30. The main
reasons for the visit were as follows: checkup (28%), con-
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traception (28%), genitourinary symptoms (18%), and pre-
natal care (18%).
Data collection. After obtaining informed consent, the
clinicians filled out a data sheet for each patient, recording
demographic information, reason for visit, prior medical
history, sexual history, signs, and symptoms. We used
standardized definitions of physical findings such as cervical
ectopy, friability, and endocervical exudate to increase
interobserver reliabiity. During the pelvic exam, clinicians
took three swabs from the endocervical canal for chlamydia
testing. They used the following order of sampling of the
cervix in each case: (i) culture for Neisseria gonorrhoeae (if
indicated), (ii) cytology test (if indicated), (iii) DFA (at
laboratory 1; swab 1), (iv) cell culture (swab 1), (v) EIA
(swab 2), and (vi) DFA (at laboratory 2; swab 3). Previous
investigators have concluded that sampling order is probably
not a factor in test outcome (4, 16). We elected not to use
cytobrushes for DFA testing because it has not been dem-
onstrated that they improve test validity and because of
concerns of clinicians regarding bleeding, patient discom-
fort, and possible disruption of known or undiagnosed preg-
nancy. Weiland et al. have subsequently reported that in
patients with positive DFA specimens collected by cyto-
brush, 100% were also positive with swab samples (20). DFA
specimens were fixed and dried according to the specifica-
tions of the manufacturer. For analysis by laboratory 2, the
DFA slide specimen was shipped by mail at ambient tem-
perature to the commercial laboratory that had previously
performed DFA tests at the health center. Patients with
positive DFA results from the commercial laboratory re-
turned within 2 weeks for treatment and were scheduled to
return to the health center 2 weeks after the start of
treatment for collection of posttreatment samples in the
manner described above.
Laboratory methods. (i) Cell culture. For isolation of C.
trachomatis from clinical specimens, a microdilution plate
procedure was used as previously described (21). We prop-
agated McCoy cells (Flow Laboratories, Inc., McLean, Va.)
in minimum essential medium (MEM) supplemented with
10% fetal calf serum, L-glutamine, nonessential amino acids,
and gentamicin (10 ,ug/ml). Cells were seeded in 96-well
microdilution plates at 6 x 104 cells per well in the same
medium and used 24 to 48 h later. Sterile cotton-tipped
plastic swabs (Scientific Products, Inc., Detroit, Mich.) were
used for collection of cervical specimens, and each swab was
placed in a tube containing 1.5 ml of 2-SP transport medium
(0.2 M sucrose, 0.02 M potassium phosphate, 0.005% phenol
red, nystatin [25 U/ml], vancomycin [25 ,ug/ml], gentamicin
[10 pig/ml]). The swab in 2-SP was mixed on a vortex mixer
three times for 15 s each, and 0.1 ml of the transport medium
per well was added to McCoy cell monolayers. The 96-well
plates were centrifuged at 1,200 x g for 1 h at room
temperature and incubated at 37°C in 5% C02 for 1 h. The
inoculum was aspirated, and 0.2 ml of supplemented MEM
plus 0.5% glucose, nystatin, vancomycin, and cyclohexi-
mide (1.5,ug/ml) per well was added. After incubation for 48
h at 37°C in 5% C02, the medium was aspirated and cells
were fixed with 95% ethanol for 10 min. After the ethanol
was removed, the monolayers were stained with fluorescein-
labeled monoclonal antibody to C. trachomatis (MicroTrak
Culture Confirmation Reagent; Syva Co., Palo Alto, Calif.)
according to the directions of the manufacturer. The stained
monolayers were examined with a fluorescence microscope
for the presence of inclusion bodies, and the approximate
numbers of inclusion bodies per well were recorded.
(ii) Direct immunofluorescent stain. The MicroTrak C.
trachomatis Direct Specimen Test (Syva Co.) was used for
DFA. Clinicians followed directions provided by the manu-
facturer to obtain patient samples and prepare slides. An
experienced technician examined the slides with a fluores-
cence microscope for chlamydial elementary bodies. We
considered a specimen inadequate if fewer than five epithe-
lial cells were visible. For analyses reported here, more than
five elementary bodies were required to declare a test
positive.
(iii) EIA. The Chlamydiazyme system (Abbott Laborato-
ries, North Chicago, Ill.) was used to detect chlamydial
antigen in the specimens. The sample collection and trans-
port kits for patient specimens were used according to the
test protocol given by the manufacturer. We stored speci-
mens at 4°C until tested (within 5 days). We performed the
assay as directed by the manufacturer and analyzed samples
with a Quantum Il spectrophotometer at a wavelength of 492
nm. The spectrophotometer automatically processed the
EIA results of the control and test specimens, yielding a
printout of a net A492 and a designation of positive or
negative for each sample.
Analysis. We calculated sensitivity, specificity, and pre-
dictive values according to standard formulas (6). Chi-square
tests, and Fisher's exact test when appropriate, were used to
compare proportions. The Mann-Whitney rank sum test was
used to compare the distribution of ordinal variables such as
inclusion counts. For comparisons of binary outcome data
when neither data source could be considered inherently
more accurate (e.g., DFA and EIA), we calculated kappa
coefficients, which adjust for agreement expected because of
chance (17). To examine associations between "exposure"
to patient or test factors and false test results, we compared
the proportion of exposed cultures among false-positives
with that among true-negatives and the proportion among
false-negatives with that among true-positives. Under the
null hypothesis, the proportions compared would be equal.
Specimens rated as inadequate were excluded from these
analyses.
RESULTS
We obtained specimens for all three tests from 276
women. Results from a DFA test performed at the commer-
cial laboratory (laboratory 2) were available for 255 of these
women. DFA results are reported for laboratory 1 unless
otherwise specified. Eight culture specimens were discarded
before laboratory analysis because of handling problems,
yielding a total of 268 complete triplicates of specimens for
culture, DFA, and EIA.
In total, 6.7% of the cultures (18 of 268) were positive for
C. trachomatis. Comparison of sensitivity, specificity, and
predictive value for EIA versus DFA (laboratory 1) revealed
lower sensitivity and a lower positive predictive value for the
DFA test (Table 1). A total of 25 DFA samples (9.1% of all
DFA samples collected) were judged to be inadequate for
reading because of an insufficient number of epithelial cells.
Exclusion of these subjects from the analysis, however, did
not significantly improve sensitivity. In addition to the
samples included in Table 1, there were 11 sets of culture,
DFA, and EIA samples collected 2 weeks after initial
treatment as "tests of cure." All 33 of these test results were
negative, indicating no false-positive antigen tests under
these circumstances. The overall concordance between EIA
and DFA tests was high (Table 2) because of the relatively
low prevalence of infection; however, we found agreement
for only 9 of 22 positive results, and the kappa coefficient
was only 0.56.
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TABLE 1. DFA and EIA methods versus ce11 culture
Rate (no. of samples/total)
Method
Sensitivity Specificity pV+a Pv-
DFA 0.50b (9/18) 0.98 (246/250) 0.69c (9/13) 0.96 (246/255)
DFA without inadequate samples 0.53 (9/17) 0.98 (223/227) 0.69 (9/13) 0.96 (223/231)
EIA 0.83b (15/18) 0.99 (247/250) 0.83c (15/18) 0.99 (247/250)
a PV, Predictive value.
b p = 0.03.
c P = 0.31, Fisher's exact test.
Lowering the cutoff value of a positive direct immunoflu-
orescent stain test (more than five elementary bodies in our
study) produced essentially no gain in sensitivity and a
decline in positive predictive value (Fig. 1). If the cutoff was
changed to two or fewer elementary bodies for a positive
test, then less than half of the positive tests would constitute
true infections. Varying the cutoff value for EIA (from the
recommended 0.1 optical density unit above controls) would
not have resulted in improved sensitivity, since false-nega-
tive EIAs were all less than 0.03 unit and lowering the cutoff
to that level would create a large number of false-positive
results.
DFA results from the two laboratories were concordant in
96% of the paired samples (Table 3). However, the kappa
coefficient was only 0.64, and of 16 samples positive for
either test, only 8 were positive for both tests. Only 3 of 246
(1.2%) DFA specimens were judged to be inadequate by
laboratory 2. None of the specimens werejudged positive by
laboratory 2 and inadequate by laboratory 1. The occurrence
of inadequate specimens in either laboratory was not asso-
ciated with date of sampling, specific clinicians, or sampling
for Neisseria gonorrhoeae or cytology prior to sampling for
C. trachomatis. For DFA, false-positive and false-negative
tests were not strongly associated with the date of testing,
smoking status, clinician, parity, pregnancy, ectopy, oral
contraceptives, menses, or recent (within 1 month) antibiotic
use. All 4 false-positive DFA subjects had no symptoms,
compared with 108 of 221 of the true-negatives (P = 0.059,
two-tailed Fisher's exact test). For EIA, all 3 false-positives
occurred in women who complained of a vaginal discharge,
compared with discharge in 89 of 245 true-negatives (P =
0.050, two-tailed Fisher's exact test).
The results in Table 4 show that false-negative results for
DFA and EIA had lower inclusion counts on culture, al-
though only three false-positive EIAs were available for
analysis. The results also show that inclusion counts were
not lower in infected women without genitourinary symp-
toms. The sensitivities of the DFA test for symptomatic and
asymptomatic women were 50 and 55%, respectively.
A total of 50% (9 of 18) of the women with chlamydial
infection reported no genitourinary symptoms. Eight of the
infected women had vaginal discharge, alone or combined
TABLE 2. Agreement between DFA and EIA2
DFA result
No. of EIA results
Positive Negative Total
Positive 9 4 13
Negative 9 254 263
Total 18 258 276
a Observed level of agreement = 0.953; kappa coefficient (correction for
chance agreement) = 0.557.
with urinary tract symptoms, and one woman had urinary
symptoms only. Table 5 shows the validity of observing
endocervical exudate (indicated by a yellowish sampling
swab) as a test for chlamydia in this population. This clinical
test had a very low sensitivity (22%) and positive predictive
value (12%), even when used strictly among symptomatic
subjects. Use of endocervical exudate in parallel with DFA
produced only a trivial increase in sensitivity over DFA
alone, with a large deterioration in positive predictive val-
ue-from 69 to 23%.
The prevalence of infection in women under 20 was 17% (9
of 53). DFA detected six of these infections, and EIA
detected all nine. In another high-prevalence subpopulation,
prenatal patients, the prevalence was 14% (7 of 49). DFA
detected only three of seven infections in this group, while
EIA detected all seven. For EIA among teens and prenatal
patients, there were no false-positives or -negatives, result-
ing in a sensitivity and specificity of 100%.
DISCUSSION
These data indicate that in a low-prevalence population in
a primary care setting (prevalence = 6.7%), EIA had a
higher sensitivity and predictive value than DFA. These
differences held whether we included inadequate DFA spec-
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FIG. 1. Effects of altering cutoffnumber of elementary bodies on
sensitivity and positive (Pos.) predictive (Pred.) value of DFA.
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TABLE 3. Agreement between DFA tests performed at two
different laboratories
No. of laboratory 1 results
Laboratory 2 result
Positive Negative Total
Positive 8 3 il
Negative 5 208 213
Total 13 211 224
a Observed level of agreement = 0.964; kappa coefficient = 0.644.
imens as negative tests or excluded them from the analysis.
In clinical practice, it is difficult to notify and quickly retest
patients whose tests were inadequate. Therefore, the infec-
tions of patients who have inadequate DFA specimens are
frequently undetected. The sensitivity of DFA was lower in
our study than in most previous ones conducted in higher-
prevalence populations. However, Tijam et al. did report a
DFA sensitivity of 46% for cervical specimens taken from
sexually transmitted disease clinic patients in The Nether-
lands (18). Some decrease in sensitivity from earlier studies
might be expected, because of the differences between the
more controlled settings of earlier studies and the more
routine sampling and transport conditions reflected in this
field study. Specificity values were high for both tests, as has
generally been observed elsewhere. In a summary of 15
studies on the DFA test, sensitivity ranged from 61 to 96% in
intermediate-prevalence populations (9 to 11%) and speci-
ficity ranged from 94 to 99% (15). It is noteworthy that in this
summary of 15 studies, the median sensitivities for EIA and
DFA were virtually equal in high-prevalence populations (89
and 90%), but in intermediate-prevalence populations, the
median sensitivity for EIA was higher-85 versus 77%. In a
gynecology clinic population with a prevalence ofonly 4.4%,
Phillips et al. reported a DFA sensitivity of 70% and a
positive predictive value of 625-both values similar to
those reported here (11).
A comparison of our results with those of four previous
studies that have simultaneously evaluated the validity of
both antigen tests reveals several important points. The
higher positive predictive values reported in three of these
studies, ranging from 85 to 93% for DFA and from 79 to
100% for EIA, result mainly from a higher prevalence of
infection, which ranged from 15.8 to 26.0% (1, 4, 16). It is
TABLE 4. Distribution of inclusion counts in positive chlamydia
cultures: false-negative versus true-positive tests and
symptomatic versus asymptomatic patients
No. of cultures with the following
Test result culture inclusion count:
or factor
1-5 6-20 21-50 51-100 >100 Total
DFA
False-negative 3 2 3 0 0 8
True-positivea 0 2 2 1 4 9
ELISAb
False-negative 2 0 0 1 0 3
True-positivec 1 4 4 1 5 15
Symptomatic 1 4 1 0 3 9
Asymptomaticd 2 0 4 1 2 9
a p = 0.o0, Mann-Whitney rank sum test.
b ELISA, Enzyme-linked immunosorbent assay.
c p = 0.15, Mann-Whitney rank sum test.
d P = 0.72, Mann-Whitney rank sum test.
TABLE 5. Endocervical exudate as a test for chlamydia
Rate
Subjects
Sensitivity Specificity pV+a PV-
All (n = 243) 0.22 0.87 0.12 0.93
Symptomatic (n = 131) 0.33 0.81 0.12 0.94
Exudate or DFA positive 0.55 0.85 0.23 0.96
a PV, Predictive value.
b Parallel test strategy: a positive result is either DFA positive or exudate
positive. Compare with results for DFA alone (Table 1) or exudate alone.
also probable, as discussed further below, that the use of
high-risk populations in these studies increased the sensitiv-
ity and negative predictive value by including a larger
proportion of severe infections and younger women. Cher-
nesky et al. (4) found that EIA had a slightly higher sensi-
tivity than DFA (98 versus 88%), while Taylor-Robinson et
al. (16) found the opposite: DFA sensitivity was 95%,
compared with 67% for EIA. Comparison with the results of
Taylor-Robinson et al. is constrained by the inclusion of
both men and women in their data. The sensitivity of both
antigen tests is presumed to be higher for women than for
men when asymptomatic subjects are included (15). In any
event, our data do not support the conclusion by Taylor-
Robinson et al. that EIA is neither sufficiently sensitive nor
sufficiently specific for routine use.
In the only other study among women in a low- or
moderate-prevalence population (prevalence = 9.7%), Smith
et al. (14) reported sensitivities for DFA and EIA of 71 and
67%, respectively. However, when they excluded as true-
positives those cases identified during a second reading of
equivocal slides by the manufacturer of the DFA test, the
sensitivity dropped to 50%. In addition, if we reanalyze their
data to count inadequate specimens as negative results, the
sensitivity drops further to 40%. Nearly 40% of the DFA
samples collected in this study, which were obtained during
routine care in obstetrics and gynecology clinics, were
judged to be inadequate. This points out the importance of
considering the criteria for specimen adequacy and the
handling of inadequate specimen results in comparing esti-
mates of DFA validity.
Since there is no a priori basis on which to assume
superior validity for either EIA or DFA, we did not calculate
sensitivity or specificity for these tests compared with each
other. In this context, in which neither test is acceptable as
a "'gold standard," the kappa coefficient can provide an
appropriate measure of agreement. It can be interpreted as
the proportion of possible excess agreement that is obtained
beyond what is expected by chance alone. The kappa
coefficient of 0.56 from our data is much lower than a kappa
coefficient of 0.90 we derived from similar data reported by
Chernesky et al. (4).
We used cell culture as the standard for comparison, but it
is possible that some infected patients might have negative
cultures (13). False-negative cultures would usually distort
the estimated validity of the antigen tests by creating more
apparent false-positive antigen tests, thus lowering speci-
ficity and positive predictive values. In a study comparing
more than one antigen test, we can make some estimates
about the occurrence of false-negative cultures. Since false-
positive antigen tests are relatively uncommon, we can
assume that most subjects with two positive antigen tests are
truly infected. Of the nine subjects with positive results in
both antigen tests, none had negative cell cultures. Using a
binomial probability model, we calculated that the upper
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boundary of a 90% confidence interval for the percentage of
false-negative cultures among those truly infected is 28%.
Therefore, we do not believe that false-negative cultures
were a substantial problem in our study, especially since
specificity, which would be the most vulnerable validity
characteristic, was already very high ftr both tests.
The manufacturer of the DFA test recommends a cutoff
number of 10 or more elementary bodies for a positive test.
Previous investigators have used less stringent cutoff
points-most often greater than or equal to five, but ranging
down to one elementary body (12). We found that a cutoffof
more than five elementary bodies gave the optimal validity
characteristics (maximum sensitivity and positive predictive
value) for the DFA test in our population, whereas Cher-
nesky et al. (4) reported that lowering the DFA cutoff to one
increased sensitivity without lowering specificity.
The interlaboratory agreement for DFA observed in this
study raises concern about the reliability of this antigen test.
Laboratory 1 used a single experienced technician, while
during the study period, laboratory 2 (a commercial lab) used
a small group of technicians who were similar to each other
in training and experience. Previous investigators have stud-
ied the agreement between readers evaluating the same DFA
slide and have concluded that disagreements are fairly
common (5). In this study, some of the discordance between
laboratories could have been due to variation in sampling
from swab to swab. This additional source of variation is
important to evaluate because it could be a major contributor
to reproducibility problems when the test is actually used in
the field. The higher number of inadequate DFA specimens
from laboratory 1 reflects a difference in the laboratory
criteria for specimen adequacy and possibly the more effi-
cient collection of epithelial cells on a subsequent swab. The
criterion of at least five epithelial cells was used by labora-
tory 1, but this number might be too high, although it did not
influence DFA validity in this study. We had expected that
certain clinicians would be responsible for an increased
share of inadequate specimens but instead found the number
of inadequate specimens to be fairly equally distributed
among the 10 clinicians who participated.
The power of this study for the detection of small or
moderate associations between false results and patient
characteristics was limited because of the low prevalence of
infection and consequently the small number of false results.
Larger numbers of false-positive and false-negative results
from antigen tests should be analyzed to provide more
precise estimates of the possible association between these
errors and specific clinical features. However, the finding
that all three false-positive EIAs were for patients with a
chief complaint of vaginal discharge could be explained by
cross-reaction with antibodies used in the tests; this phe-
nomenon has been reported in the laboratory for both
monoclonal and polyclonal antibodies (16; T. Krech, D.
Gerhard-Fsadni, N. Hoffmann, and S. M. Miller, Letter,
Lancet ii:1161-1162, 1985). Taylor-Robinson et al. reported
a cross-reaction between EIA antibody and three of seven
strains of Gardnerella vaginalis, a frequent cause of vaginitis
seen in primary care (16). Although we might expect antigen
tests to remain positive after treatment because of persisting
free antigen or nonviable organisms in the cervix, we found
no evidence for false-positive antigen tests when the tests
were used as tests for cure 2 weeks after antibiotic treat-
ment.
Our results provide evidence that false-negative results of
DFA, and perhaps of EIA, are more likely in women with
low culture inclusion counts. Thus, the proportion of sub-
jects with low infection burdens could be an important factor
in the sensitivity reported for an antigen detection method. It
is possible that low-prevalence populations such as ours
contain a higher proportion of women with low infection
burdens. This could explain, in part, the lower sensitivities
observed here in comparison with studies of higher-preva-
lence populations. We failed to find that asymptomatic
infections had lower inclusion counts, so it might not be
correct to presume that populations that include large num-
bers of asymptomatic chlamydia infections would yield
lower test sensitivities for that reason alone (8). Further
studies are needed to clarify the determinants of infection
burden in individual patients.
As others have noted, clinical predictors such as signs and
symptoms could have a role in the diagnosis of chlamydial
infections, either when used alone or in conjunction with a
rapid test. We found that the detection of yellowish exudate
on a sampling swab was by itself a very insensitive test, even
when considered among symptomatic patients only. Brun-
ham et al. have reported a sensitivity of 59% for visible
yellow exudate in a population attending a sexually trans-
mitted disease clinic (2). Consideration of endocervical
exudate in addition to DFA failed to increase sensitivity to a
significant degree. Selection of high-prevalence subpopula-
tions on the basis of clinical risk indicators can be used to
improve the positive predictive value of the antigen tests.
However, in contrast to the data reported by Smith and
co-workers (14), our results provide no evidence that the
DFA test is more sensitive for pregnant women.
On the basis of our results, EIA appears to be better than
DFA for screening low-risk primary care populations of
women for C. trachomatis infection. Despite the expense of
performing validity studies of low-prevalence populations,
more data of this nature are needed before firm conclusions
regarding the best approach to screening can be made.
Recent cost-effectiveness analyses regarding chlamydia
screening with the antigen tests have used generally higher
figures for DFA sensitivity than we have obtained. How-
ever, at least one such analysis concluded that the economic
benefits of screening with DFA were relatively impervious to
variations in test validity: with a drop in sensitivity to 70%,
costs equaled savings at an infection prevalence as low as
2.4% (19). Our data suggest that infection burden plays a
major role in DFA test sensitivity and could be an important
explanation for the differing sensitivities reported in popula-
tions with various risk profiles. Routine use of any chlamyd-
ial antigen detection method is likely to remain controversial
in primary care settings until these test accuracy issues are
clarified. Meanwhile, since genital infection with chlamydia
is so pervasive, large reductions in morbidity might depend
on aggressive programs for low- or moderate-risk popula-
tions.
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